scholarly journals Small molecule inhibitors of trans-translation have broad-spectrum antibiotic activity

2013 ◽  
Vol 110 (25) ◽  
pp. 10282-10287 ◽  
Author(s):  
N. S. Ramadoss ◽  
J. N. Alumasa ◽  
L. Cheng ◽  
Y. Wang ◽  
S. Li ◽  
...  
2020 ◽  
Vol 13 (9) ◽  
pp. 204
Author(s):  
Rodrigo A. Nava Lara ◽  
Jesús A. Beltrán ◽  
Carlos A. Brizuela ◽  
Gabriel Del Rio

Polypharmacologic human-targeted antimicrobials (polyHAM) are potentially useful in the treatment of complex human diseases where the microbiome is important (e.g., diabetes, hypertension). We previously reported a machine-learning approach to identify polyHAM from FDA-approved human targeted drugs using a heterologous approach (training with peptides and non-peptide compounds). Here we discover that polyHAM are more likely to be found among antimicrobials displaying a broad-spectrum antibiotic activity and that topological, but not chemical features, are most informative to classify this activity. A heterologous machine-learning approach was trained with broad-spectrum antimicrobials and tested with human metabolites; these metabolites were labeled as antimicrobials or non-antimicrobials based on a naïve text-mining approach. Human metabolites are not commonly recognized as antimicrobials yet circulate in the human body where microbes are found and our heterologous model was able to classify those with antimicrobial activity. These results provide the basis to develop applications aimed to design human diets that purposely alter metabolic compounds proportions as a way to control human microbiome.


FEBS Letters ◽  
1996 ◽  
Vol 380 (3) ◽  
pp. 237-240 ◽  
Author(s):  
Ionnis Vouldoukis ◽  
Yechiel Shai ◽  
Pierre Nicolas ◽  
Amram Mor

2007 ◽  
Vol 119 (25) ◽  
pp. 4768-4772 ◽  
Author(s):  
Hiranthi Jayasuriya ◽  
Kithsiri B. Herath ◽  
Chaowei Zhang ◽  
Deborah L. Zink ◽  
Angela Basilio ◽  
...  

2017 ◽  
Vol 91 (13) ◽  
Author(s):  
Fei Yi ◽  
Jia Guo ◽  
Deemah Dabbagh ◽  
Mark Spear ◽  
Sijia He ◽  
...  

ABSTRACT A dynamic actin cytoskeleton is necessary for viral entry, intracellular migration, and virion release. For HIV-1 infection, during entry, the virus triggers early actin activity by hijacking chemokine coreceptor signaling, which activates a host dependency factor, cofilin, and its kinase, the LIM domain kinase (LIMK). Although knockdown of human LIM domain kinase 1 (LIMK1) with short hairpin RNA (shRNA) inhibits HIV infection, no specific small-molecule inhibitor of LIMK has been available. Here, we describe the design and discovery of novel classes of small-molecule inhibitors of LIMK for inhibiting HIV infection. We identified R10015 as a lead compound that blocks LIMK activity by binding to the ATP-binding pocket. R10015 specifically blocks viral DNA synthesis, nuclear migration, and virion release. In addition, R10015 inhibits multiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine encephalitis virus (VEEV), and herpes simplex virus 1 (HSV-1), suggesting that LIMK inhibitors could be developed as a new class of broad-spectrum antiviral drugs. IMPORTANCE The actin cytoskeleton is a structure that gives the cell shape and the ability to migrate. Viruses frequently rely on actin dynamics for entry and intracellular migration. In cells, actin dynamics are regulated by kinases, such as the LIM domain kinase (LIMK), which regulates actin activity through phosphorylation of cofilin, an actin-depolymerizing factor. Recent studies have found that LIMK/cofilin are targeted by viruses such as HIV-1 for propelling viral intracellular migration. Although inhibiting LIMK1 expression blocks HIV-1 infection, no highly specific LIMK inhibitor is available. This study describes the design, medicinal synthesis, and discovery of small-molecule LIMK inhibitors for blocking HIV-1 and several other viruses and emphasizes the feasibility of developing LIMK inhibitors as broad-spectrum antiviral drugs.


2007 ◽  
Vol 46 (25) ◽  
pp. 4684-4688 ◽  
Author(s):  
Hiranthi Jayasuriya ◽  
Kithsiri B. Herath ◽  
Chaowei Zhang ◽  
Deborah L. Zink ◽  
Angela Basilio ◽  
...  

ACS Omega ◽  
2017 ◽  
Vol 2 (7) ◽  
pp. 3839-3857 ◽  
Author(s):  
Peter J. Cossar ◽  
Mohammed K. Abdel-Hamid ◽  
Cong Ma ◽  
Jennette A. Sakoff ◽  
Trieu N. Trinh ◽  
...  

mSphere ◽  
2021 ◽  
Author(s):  
Adrien Biessy ◽  
Amy Novinscak ◽  
Renée St-Onge ◽  
Geneviève Léger ◽  
Antoine Zboralski ◽  
...  

Plant-beneficial phenazine-producing Pseudomonas spp. are effective biocontrol agents, thanks to the broad-spectrum antibiotic activity of the phenazine antibiotics they produce. These bacteria have received considerable attention over the last 20 years, but most studies have focused only on the ability of a few genotypes to inhibit the growth of a limited number of plant pathogens.


Sign in / Sign up

Export Citation Format

Share Document